Next Generation News and Research

RSS

Surgeons at French hospital perform first Navio UKR procedures

Blue Belt Technologies announces the first Navio™ unicondylar knee replacement (UKR) procedures performed in France, completed on September 30th, October 15th and Nov 4th 2013 by Professor Philippe Neyret and Dr. Sébastien Lustig at Hospices Civils de Lyon in France.

23 Dec 2013

Icahn School of Medicine receives $1.3M grant to build collaborative research infrastructure for stroke center

23 Dec 2013

Researchers investigate how androgen receptors affect prostate cancer progression

Approximately 1 out of every 6 American men will be diagnosed with prostate cancer, and this year alone there are expected to be nearly a quarter of a million new cases diagnosed, making prostate cancer the most common malignancy among men in the United States. Center for Nuclear Receptors & Cell Signaling Assistant Professor Daniel Frigo and his research team recently published a study investigating the processes through which androgen receptors affect prostate cancer progression.

22 Dec 2013

Icahn School of Medicine at Mount Sinai joins NIH Stroke Trials Network

The Icahn School of Medicine at Mount Sinai joins a top-flight network of 25 regional stroke centers announced by the National Institute of Health that will focus on prevention, treatment, and recovery from stroke. As part of the NIH Stroke Trials Network (NIHStrokeNet), the medical school will receive a 5-year, $1.3 million grant to build a collaborative research infrastructure for a regional coordinating stroke center.

20 Dec 2013

Sugar-based gelators may provide alternatives to trans fats linked to obesity, heart disease, diabetes

Researchers at The City College of New York have reported the successful transformation of vegetable oils to a semisolid form using low-calorie sugars as a structuring agent.

20 Dec 2013

MicuRx announces initiation of global clinical development program for MRX-I compound

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the initiation of a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

20 Dec 2013

Merck and CNIO sign agreement to collaborate in area of cancer drug development

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development.

19 Dec 2013

Computer-controlled, rotating table could deliver high doses of radiotherapy to tumors, spare vulnerable organs

Swivelling patients around on a computer-controlled, rotating table could deliver high doses of radiotherapy to tumours more quickly than current methods, while sparing vulnerable organs such as the heart, brain, eyes and bowel.

19 Dec 2013

LSDF announces research and development grants to commercialize health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced $1.1 million in five Proof of Concept grants to Washington for-profit and non-profit organizations to foster the translation of health-related products from the laboratory into the commercial marketplace.

19 Dec 2013

Merck signs license agreement with CNIO for cancer drug development

Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

18 Dec 2013

Professor wins $1M to create medical devices that lead to greater control of prosthetics in soldiers

Dr. Walter Voit, assistant professor of materials science and engineering and mechanical engineering at The University of Texas at Dallas, has been awarded $1 million to create medical devices that will lead to greater control of prosthetics in wounded soldiers.

17 Dec 2013

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.

16 Dec 2013

ACA sets standards to ensure that consumers get coverage options in every state in the U.S.

As health insurance moves to a direct-to-consumer model, identifying where consumers are located and what health plan options are available in local markets is essential. The Affordable Care Act is reshaping the industry and setting standards to ensure that consumers have coverage options in all geographies of every state in the U.S. Companies participating in the Marketplace (Exchanges) are using county market share and penetration rates to identify underinsured opportunities for Medicaid and Commercial market expansion.

16 Dec 2013

Psychology researchers and practitioners still hold different beliefs about repressed memories

Skepticism about repressed traumatic memories has increased over time, but new research shows that psychology researchers and practitioners still tend to hold different beliefs about whether such memories occur and whether they can be accurately retrieved.

13 Dec 2013

Researchers uncover second rare genetic mutation linked to higher risk of Alzheimer's disease

A research team from The University of Nottingham has helped uncover a second rare genetic mutation which strongly increases the risk of Alzheimer's disease in later life.

13 Dec 2013

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University today announced they have entered into a five-year, $6.5 million research collaboration.

12 Dec 2013

New family of drugs may help combat childhood tumor

St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor

11 Dec 2013

BD Diagnostics introduces two ESR instruments to improve patient care in point of care settings

BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.

From BD (Becton, Dickinson and Company) 11 Dec 2013

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014.

From NanoString Technologies 11 Dec 2013

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.

10 Dec 2013

Next Generation News and Research

Surgeons at French hospital perform first Navio UKR procedures

Icahn School of Medicine receives $1.3M grant to build collaborative research infrastructure for stroke center

Researchers investigate how androgen receptors affect prostate cancer progression

Icahn School of Medicine at Mount Sinai joins NIH Stroke Trials Network

Sugar-based gelators may provide alternatives to trans fats linked to obesity, heart disease, diabetes

MicuRx announces initiation of global clinical development program for MRX-I compound

Merck and CNIO sign agreement to collaborate in area of cancer drug development

Computer-controlled, rotating table could deliver high doses of radiotherapy to tumors, spare vulnerable organs

LSDF announces research and development grants to commercialize health-related technologies

Merck signs license agreement with CNIO for cancer drug development

Professor wins $1M to create medical devices that lead to greater control of prosthetics in soldiers

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

ACA sets standards to ensure that consumers get coverage options in every state in the U.S.

Psychology researchers and practitioners still hold different beliefs about repressed memories

Researchers uncover second rare genetic mutation linked to higher risk of Alzheimer's disease

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

New family of drugs may help combat childhood tumor

BD Diagnostics introduces two ESR instruments to improve patient care in point of care settings

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News